Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Relative Value
The Relative Value of one PHAT stock under the Base Case scenario is 10.81 USD. Compared to the current market price of 9.18 USD, Phathom Pharmaceuticals Inc is Undervalued by 15%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
PHAT Competitors Multiples
Phathom Pharmaceuticals Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
|
532m USD | 780 | -2.6 | -3.5 | -3.5 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
696.4B USD | 20.4 | 132.9 | 60.1 | 68.9 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 17 | 47.2 | 34.6 | 37.7 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
JP |
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 255.8 | 9 733.7 | 1 771.8 | 4 320.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
351.8B USD | 4.3 | 8.7 | 11.6 | 15.3 | ||
US |
Merck & Co Inc
NYSE:MRK
|
332.2B USD | 5.5 | 910 | 45.2 | 88.2 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
185.8B GBP | 5.1 | 39 | 140.5 | 225.4 | ||
CH |
Novartis AG
SIX:NOVN
|
182.9B CHF | 4.3 | 13.5 | 9.9 | 16.3 | ||
CH |
Roche Holding AG
SIX:ROG
|
176.2B CHF | 3 | 15.3 | 8.5 | 10 |